Cargando…

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

OBJECTIVE AND DESIGN: Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment. Our objective was to evaluate whether lanreotide Autogel® 120 mg, every 4–8 weeks, was as effective in control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucas, T, Astorga, R
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2006
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1618957/ https://www.ncbi.nlm.nih.gov/pubmed/16918950 http://dx.doi.org/10.1111/j.1365-2265.2006.02595.x

Ejemplares similares

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
por: Caron, Philippe J., et al.
Publicado: (2014)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
por: Caron, Philippe J., et al.
Publicado: (2015)

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
por: An, Zhenmei, et al.
Publicado: (2020)

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
por: Petersenn, Stephan, et al.
Publicado: (2019)

Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
por: Alvarez-Escola, Cristina, et al.
Publicado: (2015)

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014)

Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy
por: Schoeters, Patrick, et al.
Publicado: (2015)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
por: Aerts, Maridi, et al.
Publicado: (2017)

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
por: Zafra, Gema Marín, et al.
Publicado: (2016)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Primary treatment of acromegaly with high-dose lanreotide: a case series
por: Wuster, Christian, et al.
Publicado: (2010)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

A New Approach to Supramolecular Structure Determination in Pharmaceutical Preparation of Self-Assembling Peptides: A Case Study of Lanreotide Autogel
por: Grimaldi, Manuela, et al.
Publicado: (2022)

Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report
por: Tanaka, Sho, et al.
Publicado: (2017)

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(®) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
por: Melmed, Shlomo, et al.
Publicado: (2009)

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014)

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-month phase of Lanro-Study
por: Orlewska, Ewa, et al.
Publicado: (2013)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

Anomalous dynamics of water at the octopeptide lanreotide surface
por: Pinzan, Florian, et al.
Publicado: (2020)

Real world use of lanreotide in neuroendocrine tumors
por: Siddiqui, Zeba, et al.
Publicado: (2023)

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional
por: Johanson, Viktor, et al.
Publicado: (2012)

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study
por: Ito, Tetsuhide, et al.
Publicado: (2020)

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
por: Martín-Richard, Marta, et al.
Publicado: (2013)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mjqbf6lpfe07g0udbqh6af2dtb